A poster analysis of the phase 3 ADVANCE OUTCOMES trial, presented at the CHEST 2026 Annual Meeting in Phoenix, Arizona, found that oral ralinepag reduced clinical worsening across different baseline risk profiles in patients with pulmonary arterial hypertension (PAH).
Jean Elwing, MD, FCCP, Professor of Clinical Internal Medicine at the University of Cincinnati, discusses the findings and their implications for PAH treatment.
Understanding Pulmonary Arterial Hypertension and Risk Assessment
PAH is a rare, progressive lung disease classified as Group 1 pulmonary hypertension that affects about 15 to 50 people per million in the U.S. and Europe. It’s characterized by increased resistance in the pulmonary blood vessels, placing additional strain on the right side of the heart and potentially leading to right heart failure.
Treatment decisions for PAH are guided by risk assessment. This lets clinicians estimate a patient’s risk of poor outcomes, including mortality over the following year. Dr. Elwing explained that clinicians use several risk-scoring tools, including the French non-invasive risk criteria, to evaluate patients and guide treatment.
The French non-invasive criteria evaluate three measures:
- Functional class I or II
- Six-minute walk distance (6MWD) greater than 440 meters
- N-terminal pro-B-type natriuretic peptide (NT-proBNP) of 300 pg/mL or less
Ralinepag is an investigational, oral, once-daily selective prostacyclin IP receptor agonist that targets the prostacyclin pathway, one of the pathways used in PAH treatment.
ADVANCE OUTCOMES Demonstrates Reduced Clinical Worsening With Ralinepag
ADVANCE OUTCOMES (NCT03626688) was a global, randomized, double-blind, placebo-controlled phase 3 trial evaluating ralinepag in patients with PAH. Results of the study were published on August 8, 2026, in The Lancet.
ADVANCE OUTCOMES enrolled 687 patients, randomized to receive ralinepag or placebo. Approximately 80% of those patients were receiving dual background PAH therapy.1
The primary endpoint was time to first clinical worsening event, defined by a composite of:
- Death from any cause
- Hospitalization due to worsening PAH or right heart failure
- Initiation of parenteral or inhaled prostacyclin-pathway therapy
- Disease progression
- Unsatisfactory long-term clinical response
The study found that 18% of patients receiving ralinepag experienced a clinical worsening event compared with 36% receiving placebo, representing a 55% relative reduction in risk (HR 0.45; P less than 0.0001).1
Dr. Elwing noted that the parent study also demonstrated positive secondary outcomes, including improvements in walk distance and NT-proBNP.
Ralinepag Shows Favorable Effects Across Different Risk Profiles
The poster analysis examined whether baseline risk profiles influenced the treatment effects of ralinepag. Researchers evaluated 681 patients with available baseline assessments using the three French non-invasive low-risk criteria.
Dr. Elwing said the analysis found that 12.3% of patients had none of the three low-risk features, and more than 60% had two or three low-risk features.
Ralinepag demonstrated a favorable direction of treatment effect across all subgroups, with the largest numerical relative effect observed among patients meeting all three low-risk criteria. Improvements in six-minute walk distance and NT-proBNP were also observed across subgroups, with the strongest numerical NT-proBNP reduction among patients meeting all three criteria.
Dr. Elwing said these findings were exploratory. The analysis didn’t determine whether the treatment effect was statistically greater among patients meeting all three criteria, so additional research will be necessary.
Residual Disease Risk in PAH Treatment
Just because some patients achieved conventional low-risk thresholds, it doesn’t necessarily mean PAH won’t progress. Dr. Elwing shared that the study’s findings suggest patients may continue to benefit from treatment optimization even if they have multiple low-risk criteria.
The poster analysis supports continued evaluation of residual disease risk and clinical worsening beyond traditional low-risk thresholds. It’s also important to note that the subgroup findings should be interpreted cautiously. The analysis featured a relatively small sample, and no interaction testing was reported.
In Their Own Words
“In ADVANCE OUTCOMES, ralinepag demonstrated a favorable effect on clinical worsening even among patients meeting all three low-risk French non-invasive criteria, supporting continued attention to disease progression and potential for further optimization.”
– Jean Elwing, MD, FCCP, Professor of Clinical Internal Medicine at the University of Cincinnati
For more information, visit: https://events.rdmobile.com/Lists/Details/3689009
To learn more about pulmonary arterial hypertension and other rare lung diseases, visit: https://checkrare.com/diseases/lung-diseases/
